|
1
|
Hasle H: Myelodysplastic and
myeloproliferative disorders of childhood. Hematology Am Soc
Hematol Educ Program. 2016:598–604. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Locatelli F and Strahm B: How I treat
myelodysplastic syndromes of childhood. Blood. 131:1406–1414.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pastor V, Hirabayashi S, Karow A, Wehrle
J, Kozyra EJ, Nienhold R, Ruzaike G, Lebrecht D, Yoshimi A,
Niewisch M, et al: Mutational landscape in children with
myelodysplastic syndromes is distinct from adults: Specific somatic
drivers and novel germline variants. Leukemia. 31:759–762.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Passmore SJ, Chessells JM, Kempski H, Hann
IM, Brownbill PA and Stiller CA: Paediatric myelodysplastic
syndromes and juvenile myelomonocytic leukaemia in the UK: A
population-based study of incidence and survival. Br J Haematol.
121:758–767. 2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dufour C, Schwarz-Furlan S, Baumann I,
Rudelius M, Nöllke P, Lebrecht D, Ramamoorthy S, Rotari N, Karow A,
Hirabayashi S, et al: Long-term outcomes of patients with
refractory cytopenia of childhood under observation only. Blood
Adv. 9:4279–4285. 2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yoshimi A, Baumann I, Führer M,
Bergsträsser E, Göbel U, Sykora KW, Klingebiel T, Gross-Wieltsch U,
van den Heuvel-Eibrink MM, Fischer A, et al: Immunosuppressive
therapy with anti-thymocyte globulin and cyclosporine A in selected
children with hypoplastic refractory cytopenia. Haematologica.
92:397–400. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Garcia-Manero G, Jabbour E, Borthakur G,
Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N,
Berdeja JG, et al: Randomized open-label phase II study of
decitabine in patients with low- or intermediate-risk
myelodysplastic syndromes. J Clin Oncol. 31:2548–2553.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Thiele J, Kvasnicka HM, Facchetti F,
Franco V, van der Walt J and Orazi A: European consensus on grading
bone marrow fibrosis and assessment of cellularity. Haematologica.
90:1128–1132. 2005.PubMed/NCBI
|
|
9
|
Garcia-Manero G: Myelodysplastic
syndromes: 2023 update on diagnosis, risk-stratification, and
management. Am J Hematol. 98:1307–1325. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW (eds): WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues.
4th edition. IARC Press, Lyon, 2008.
|
|
11
|
Shimamura A and Alter BP: Pathophysiology
and management of inherited bone marrow failure syndromes. Blood
Rev. 24:101–122. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rudelius M, Weinberg OK, Niemeyer CM,
Shimamura A and Calvo KR: The international consensus
classification (ICC) of hematologic neoplasms with germline
predisposition, pediatric myelodysplastic syndrome, and juvenile
myelomonocytic leukemia. Virchows Arch. 482:113–130.
2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Baumann I, Führer M, Behrendt S, Campr V,
Csomor J, Furlan I, de Haas V, Kerndrup G, Leguit RJ, De Paepe P,
et al: Morphological differentiation of severe aplastic anaemia
from hypocellular refractory cytopenia of childhood:
Reproducibility of histopathological diagnostic criteria.
Histopathology. 61:10–17. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Westers TM, Ireland R, Kern W, Alhan C,
Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della
Porta MG, et al: Standardization of flow cytometry in
myelodysplastic syndromes: A report from an international
consortium and the European LeukemiaNet Working Group. Leukemia.
26:1730–1741. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kennedy AL and Shimamura A: Genetic
predisposition to MDS: Clinical features and clonal evolution.
Blood. 133:1071–1085. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sahoo SS, Pastor VB, Goodings C, Voss RK,
Kozyra EJ, Szvetnik A, Noellke P, Dworzak M, Starý J, Locatelli F,
et al: Clinical evolution, genetic landscape and trajectories of
clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med.
27:1806–1817. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kozyra EJ, Hirabayashi S, Loyola VBP,
Przychodzen B, Karow A, Catala A, De Moerloose B, Dworzak M, Hasle
H, Masetti R, et al: Clonal mutational landscape of childhood
myelodysplastic syndromes. Blood. 126(1662)2015.
|
|
18
|
Hasegawa D, Chen X, Hirabayashi S, Ishida
Y, Watanabe S, Zaike Y, Tsuchida M, Masunaga A, Yoshimi A, Hama A,
et al: Clinical characteristics and treatment outcome in 65 cases
with refractory cytopenia of childhood defined according to the WHO
2008 classification. Br J Haematol. 166:758–766. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ren Y, Liu F, Chen X, Zhang X, Zhao B, Wan
Y, Lan Y, Li X, Yang W, Zhu X and Guo Y: Decitabine-containing
conditioning improved outcomes for children with higher-risk
myelodysplastic syndrome undergoing allogeneic hematopoietic stem
cell transplantation. Ann Hematol. 103:1345–1351. 2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gao J, Hu Y, Gao L, Xiao P, Lu J and Hu S:
The effect of decitabine-combined minimally myelosuppressive
regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10
years' experience of a single center. BMC Pediatr.
22(312)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Schwartz JR, Ma J, Lamprecht T, Walsh M,
Wang S, Bryant V, Song G, Wu G, Easton J, Kesserwan C, et al: The
genomic landscape of pediatric myelodysplastic syndromes. Nat
Commun. 8(1557)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kantarjian H, Issa JPJ, Rosenfeld CS,
Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C,
Ravandi F, et al: Decitabine improves patient outcomes in
myelodysplastic syndromes: Results of a phase III randomized study.
Cancer. 106:1794–1803. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kantarjian H, Oki Y, Garcia-Manero G,
Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F,
Estrov Z, et al: Results of a randomized study of 3 schedules of
low-dose decitabine in higher-risk myelodysplastic syndrome and
chronic myelomonocytic leukemia. Blood. 109:52–57. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Glasser CL, Lee A, Eslin D, Marks L, Modak
S and Glade Bender JL: Epigenetic combination therapy for children
with secondary myelodysplastic syndrome (MDS)/acute myeloid
leukemia (AML) and concurrent solid tumor relapse. J Pediatr
Hematol Oncol. 39:560–564. 2017.PubMed/NCBI View Article : Google Scholar
|
